Pharmaceuticals

Small Molecule Targeted Therapy Market Trends and Insights: Global Forecast to 2030

February 18, 2026February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the small molecule targeted therapy market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Small Molecule Targeted Therapy Market between 2026 and 2030?

The small molecule targeted therapy market size has experienced substantial expansion in recent years. It is anticipated to increase from $77.29 billion in 2025 to $84.66 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.5%. This historical growth can be attributed to advancements in molecular biology research, the growing prevalence of chronic diseases, the expansion of pharmaceutical R&D pipelines, the regulatory acceptance of targeted therapies, and improvements in drug screening technologies.

The small molecule targeted therapy market is poised for significant expansion in the coming years. Projections indicate it will reach $120.64 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.3%. This projected growth during the forecast period is fueled by factors such as the escalating demand for personalized medicine, the increasing incorporation of genomics into drug development, the broadening application of targeted therapies beyond cancer treatment, a heightened emphasis on drug design optimized for safety, and rising investments in precision therapeutics. Key trends anticipated during this period encompass the continued growth in the development of target-specific drugs, the expanding utilization of therapies that modulate specific pathways, the increasing acceptance of oral small molecule treatments, a sharper focus on molecular targets specific to diseases, and the wider implementation of combination small molecule regimens.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28332&type=smp

Which Drivers Are Expected To Impact The Small Molecule Targeted Therapy Market During The Forecast Period?

The increasing focus on personalized medicine is anticipated to fuel the expansion of the small molecule targeted therapy market in the future. Personalized medicine is defined as a healthcare strategy that customizes prevention, diagnosis, and treatment based on an individual’s genetic makeup, environmental influences, and lifestyle choices. The rise of personalized medicine stems from progress in genomics, which facilitates a more profound comprehension of individual genetic differences, leading to more accurate, targeted therapies that enhance patient results and minimize experimental approaches in treatments. Small molecule targeted therapy facilitates personalized medicine by precisely targeting a patient’s unique molecular or genetic disease characteristics, thereby boosting treatment effectiveness and mitigating adverse reactions. For example, data from February 2024 by the Personalized Medicine Coalition, a US-based non-profit organization, indicates that in 2023, the FDA sanctioned 16 novel personalized treatments for rare disease patients, an increase from six in 2022. Among the new personalized treatments approved in 2023 were also seven cancer drugs and three for other diseases and conditions. Consequently, the heightened focus on personalized medicine is a key factor propelling the expansion of the small molecule targeted therapy market.

Which Segments Are Driving Activity In The Small Molecule Targeted Therapy Market?

The small molecule targeted therapy market covered in this report is segmented –

1) By Type Of Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Drug Class: Monoclonal Antibodies, Small Molecule Inhibitors, Combination Therapies

3) By Mechanism Of Action: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (Ahr) Modulators, Cell Cycle Inhibitors

4) By Disease Indication: Cancer, Autoimmune Diseases, Infectious Diseases

5) By Route Of Administration: Oral, Intravenous, Subcutaneous

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-microtubule Agents

2) By Targeted Therapy: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (AhR) Modulators

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

How Are Emerging Trends Affecting The Progression Of The Small Molecule Targeted Therapy Market?

Leading companies operating within the small molecule targeted therapy market are concentrating on developing innovative solutions, such as oral small molecules, to enhance targeted delivery, improve patient compliance, and address particular molecular pathways in both oncology and other chronic ailments. An oral small molecule is a low-molecular-weight drug that can be consumed by mouth, engineered to easily enter cells and specifically target disease-related proteins or pathways. For instance, in June 2025, Kura Oncology Inc., a US-based biotech company, obtained an FDA approval for a New Drug Application (NDA) for ziftomenib as a therapy for adult patients with relapsed or refractory acute myeloid leukemia (AML) presenting nucleophosmin 1 (NPM1) mutations. This oral targeted therapy is specifically designed for adult patients with relapsed or refractory AML harboring NPM1 mutations, thereby fulfilling a significant unmet medical need. It features a favorable safety profile and has shown promising efficacy, including notable complete remission rates in clinical trials. Through the selective inhibition of the menin-KMT2A interaction, ziftomenib disrupts the growth of leukemic cells and supports new treatment options for this difficult-to-treat AML subtype.

Which Major Firms Are Strengthening Their Position In The Small Molecule Targeted Therapy Market?

Major companies operating in the small molecule targeted therapy market are F. Hoffmann-La Roche AG (Roche), Merck KGaA, Pfizer Inc., Bayer AG, Sanofi S.A., Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, Blueprint Medicines Corporation, Kura Oncology Inc., G1 Therapeutics Inc., Ascentage Pharma Group International Inc., Rgenta Therapeutics Inc., Verastem Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-therapy-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Small Molecule Targeted Therapy Market?

North America was the largest region in the small molecule targeted therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Small Molecule Targeted Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28332&type=smp

Browse Through More Reports Similar to the Global Small Molecule Targeted Therapy Market 2026, By The Business Research Company

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795